You are here

  • Home
  • Archive
  • Volume 67, Issue 8
  • Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate

Article info

Article menu

Download PDFPDF

Extended report
Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate

Authors

  1. Dr M Schiff, Denver Arthritis Clinic, 200 Spruce Street #100, Denver, CO 80230, USA; Lmschiff{at}aol.com
View Full Text

Citation

Schiff M, Keiserman M, Codding C, et al
Efficacy and safety of abatacept or infliximab vs placebo in ATTEST: a phase III, multi-centre, randomised, double-blind, placebo-controlled study in patients with rheumatoid arthritis and an inadequate response to methotrexate
Annals of the Rheumatic Diseases 2008;67:1096-1103.

Publication history

  • Accepted November 17, 2007
  • First published November 29, 2007.
Online issue publication 
October 25, 2017

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

2008 BMJ Publishing Group and European League Against Rheumatism